EU regulator builds Omicron defences with approvals of Vir, Sobi drugs

* EMA approves Kineret and Xevudy for COVID-19 treatment

* Kineret for adults with pneumonia, lung failure risk

* Xevudy for adults, adolescents at risk of severe disease

By Pushkala Aripaka and Amna Karimi

Dec 16 (Reuters) - The European Union's drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK GSK.L and Vir Biotechnology VIR.O and another from Swedish drugmaker Sobi SOBIV.ST , as the bloc builds its defences against Omicron.

The approval by the European Medicines Agency (EMA) of GSK-Vir's antibody drug Xevudy and Sobi's arthritis drug Kineret come as governments struggle with soaring infections and worry about the swiftly-spreading Omicron variant of the coronavirus.

EMA's human medicines committee recommended using Kineret to treat COVID-19 in adults with pneumonia requiring oxygen support and those at risk of developing severe respiratory failure.

GSK-Vir's Xevudy, chemically called sotrovimab, was recommended for adults and adolescents who did not require oxygen support but faced a higher risk their disease could worsen.

While a small number of allergic reactions were seen with Xevudy, its benefits outweighed any risks, as did Kineret's, EMA said.

With the latest approvals, the EU has approved six medicines for use against COVID-19. EMA okayed drugs from Regeneron-Roche REGN.O ROG.S and Celltrion 091990.KQ last month.

GSK-Vir's sotrovimab has shown to be effective against all mutations of Omicron in lab studies, paving the way for wider use in populations. EMA had already advised on its use to help member states before the EU-wide green light.

Sotrovimab belongs to a class of drugs called monoclonal antibodies which are lab generated proteins meant to mimic the body's natural defences against infections. Regeneron-Roche's similar therapy does not have the same efficacy against Omicron.


The European Union's public health body warned on Wednesday that there was a "very high" risk Omicron would become dominant in Europe by early next year.

Sobi's Kineret is primarily used to treat rheumatoid arthritis as the drug reduces the activity of the immune system and a chemical messenger in the immune process that causes inflammation.

COVID-19 patients with severe symptoms including pneumonia are believed to suffer from an overreaction of the immune system known as cytokine storm, which drugs such as Kineret have shown to control.

Final and formal approvals are up to the European Commission (EC), which typically endorses EMA recommendations. EMA said it would send its advice to the Commission for a "rapid decision".

Other approved COVID-19 treatments in the EU are Regeneron-Roche's antibody cocktail Ronapreve, Celltrion's antibody drug Regkirona, Roche's arthritis drug RoActemra and Gilead's GILD.O antiviral infusion remdesivir.

EMA is also reviewing AstraZeneca's AZN.L antibody cocktail and COVID-19 pills from Merck MRK.N and Pfizer PFE.N .

Omicron set to be Europe's dominant variant by early 2022 - ECDC

COVID SCIENCE-Omicron thrives in airways, not lungs; new data on asymptomatic cases

FACTBOX-Front runners in development of antibody drugs against COVID-19

FACTBOX-What COVID-19 vaccine and drug makers have to say about Omicron

Reporting by Pushkala Aripaka and Amna Karimi in Bengaluru; Editing by Edmund Blair

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.